
Education
PhD, Leningrad State University
MPH, Columbia University
Biography
- I am the leader of the group that has an expertise in the analysis of large Healthcare data sets. The goal of the local, state and national health and administrative hospital data sets analysis is to provide an independent assessment of outcomes outside of the controlled experimental conditions of clinical trials to help providers, policy makers and patients with decision-making in Healthcare. Our group maintains and updates a library of more than a decade worth of state-wide hospital discharge data sets; e.g. of New York State, Florida, New Jersey, and California. It also has a library of national databases, such as the Nationwide Inpatient Sample (NIS), Nationwide Emergency Department Sample (NEDS), the National Hospital Discharge Survey (NHDS), as well as the Medicare discharge data set for AAA repairs, which alone contains more than 210 million records, and for Medicare Heart Failure patients. We analyze the LifeLine screen - the biggest data base of screening for vascular diseases in the United States. I have been involved in a wide variety of research projects at the Mount Sinai School of Medicine where I played an integral role in these analyses, working closely with the clinical investigators.
Awards
1988 -
Researcher's Award in Biology
Puschino Academic Research Center1982 -
Competitions of young investigators award
Leningrad State University
Research
Evaluation of obstetric quality indicatiors
Evaluation of trend in obstetrical-related quality indicators and examination whether these indicators differ for Blacks and Whites and if the difference may explain racial disparities in maternal and neonatal mortality rates.Risk factors for development of vascular diseases and analyses of surgical treatment outcomes for patients with different risk profiles
Comparison of outcomes after traditional and endovascular treatment of vascular peripheral diseases; analysis of risk factors for development of vascular diseases; gender impact on vascular diseases treatment outcomes; identification of high risk patients for endovascular treatments, development of risk score to identify high risk patients for minimally invasive procedures.Outcomes of treatment of degenerative spine diseases
National and state analysis of different surgical treatment of degenerative disorders of the thoracic and lumbar spine.Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Egorova did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd Room L2-70
1425 Madison Avenue
New York, NY 10029


